B-Cell Lymphomas, Version 6.2023 Featured Updates to the NCCN Guidelines

jugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in themanagement ofmantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19CAR T-cell therapies are noweffective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), andMCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, andMCL.